Examples of using Soliris in English and their translations into Portuguese
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
was improved during Soliris therapy.
increased during Soliris therapy.
Instructions for Use for Healthcare Professionals Handling Soliris.
After 3 weeks of Soliris treatment, patients reported less fatigue
After the fifth week, your doctor will administer 1,200 mg of diluted Soliris every two weeks as a long-term treatment.
All patients received Soliris and the study measured the number of red blood cell transfusions needed during the 12 weeks of treatment.
The risks of stopping Soliris include an increase in the destruction of your red blood cells,
The risks of stopping Soliris include an increase in the inflammation of your platelets,
Soliris has not been studied in children
Because of an increased risk of meningitis, Soliris should not be given to people who are infected with Neisseria meningitidis,
Prior to initiating Soliris therapy, it is recommended that PNH patients should receive immunizations according to current immunization guidelines.
After 3 weeks of Soliris treatment, patients reported less fatigue
Soliris therapy must not be initiated without prior vaccination against Neisseria meningitidis at least 2 weeks prior to initial administration.
Soliris treatment may reduce your natural resistance to infections, especially against certain organisms that cause meningitis.
Maintenance Phase:• After the fifth week, your doctor will administer 900 mg of diluted Soliris every two weeks as a long-term treatment.
What Soliris looks like and contents of the pack Soliris is presented as a concentrate for solution for infusion 30 ml in a vial- pack size of 1.
Supplemental dosing is recommended when Soliris is administered to aHUS patients receiving plasma infusion
the median duration of Soliris therapy was approximately 114 weeks range: 26 to 129 weeks.
Due to its mechanism of action, Soliris therapy should be administered with caution to patients with active systemic infections.
Soliris administration should be interrupted in all patients experiencing severe infusion reactions and appropriate medical therapy administered.